Association of lipid peroxidation and interleukin-6 with carotid atherosclerosis in type 2 diabetes.

Cardiovasc Endocrinol Metab

Departments of Internal Medicine, Diabetes, Lipidology and Metabolism Unit.

Published: September 2019

Unlabelled: Enhanced lipid peroxidation and elevated interleukin-6 levels are common in type 2 diabetes mellitus patients. Atherosclerotic vascular complications greatly contribute to morbidity and mortality in diabetes. The aim of this study was to assess the relation of lipid peroxidation and interleukin-6 with carotid atherosclerosis in type 2 diabetes mellitus.

Methods: This cross-sectional study included 90 type 2 diabetes mellitus male patients with age ≥ 40 years and 30 healthy male subjects matched for age. All of them were subjected to measuring of 8-iso prostaglandin F2α as a marker of lipid peroxidation, interleukin-6 and carotid intima media thickness as a marker of carotid atherosclerosis.

Results: Both 8-iso prostaglandin F2α and interleukin-6 were found to have significant positive correlation with carotid intima media thickness ( < 0.001) and both were found to be significant predictors of the presence of subclinical carotid atherosclerosis in multiple regression analysis.

Conclusion: Lipid peroxidation and interleukin-6 may play an important role in atherogenesis in type 2 diabetes mellitus and limiting their effects may reduce atherosclerotic vascular complications in type 2 diabetes mellitus.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779841PMC
http://dx.doi.org/10.1097/XCE.0000000000000175DOI Listing

Publication Analysis

Top Keywords

type diabetes
24
lipid peroxidation
20
peroxidation interleukin-6
16
diabetes mellitus
16
interleukin-6 carotid
12
carotid atherosclerosis
12
atherosclerosis type
8
atherosclerotic vascular
8
vascular complications
8
8-iso prostaglandin
8

Similar Publications

Glycemic and weight control in people with type 2 diabetes: A real-world observational study in primary care.

Prim Care Diabetes

December 2024

Endocrinology and Nutrition Service, Santa Creu i Sant Pau Hospital, Autonomous University of Barcelona, Barcelona, Spain; Biomedical Research Networking Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), Carlos III Health Institute (ISCIII), Barcelona, Spain; Spanish Diabetes Society, Former President, Spain.

Aims: To analyze glycemic and bodyweight control in people with type 2 diabetes mellitus (T2DM), and prescribing patterns in primary care.

Methods: We reviewed the electronic medical records of 5009 randomly selected T2DM patients, from 70 health centers in Spain. We analyzed results by age group and presence/absence of obesity.

View Article and Find Full Text PDF

Objectives: To assess the factors associated with foot self-care behaviour and non-adherence to foot screening among patients with type 2 diabetes mellitus (T2DM).

Design And Setting: A multicentre cross-sectional study was undertaken in seven primary care polyclinics in Singapore between October 2020 and December 2021.

Participants And Outcomes: 275 adults (male 55.

View Article and Find Full Text PDF

Background/aim: Imeglimin, a novel oral antidiabetic agent, was approved in 2021 for the treatment of type 2 diabetes mellitus (T2DM). Phase III clinical trials demonstrated its safety and efficacy in managing T2DM. However, its safety profile in patients with heart failure has not been thoroughly evaluated in real-world clinical settings.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!